Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myeloma

Miriam Y. Kim, Richard Sposto, Abhisek Swaika, Hitomi Asano, Ahsan Alamgir, Asher A Chanan Khan, Sikander Ailawadhi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We compared the three arms of the MM-015 randomized phase III clinical trial [melphalan and prednisone (MP), MP plus lenalidomide (MPR), and MPR plus lenalidomide maintenance (MPR-R)] to determine whether the addition of lenalidomide maintenance therapy for primary treatment of multiple myeloma is cost-effective. We used progression-free survival and adverse event data from the MM-015 study for the analysis. Two novel measures of cost-effectiveness termed the Average Cumulative Cost per Patient (ACCP) and the Average Cumulative Cost per Progression-Free Survivor (ACCPFS) were developed for the purpose of this analysis. The ACCP of MP was USD 18,218, compared to USD 167,862 for MPR and USD 309,173 for MPR-R. The ACCPFS was highest with MPR at USD 1,555,443, while MP was USD 313,592 and MPR-R was USD 690,111. MPR-R is superior to MPR in terms of preventing the first progression after initial therapy. However, the addition of lenalidomide to MP in the induction and also in the maintenance setting leads to significant costs.

Original languageEnglish (US)
Pages (from-to)224-231
Number of pages8
JournalOncology (Switzerland)
Volume87
Issue number4
DOIs
StatePublished - Nov 7 2014

Fingerprint

Pharmaceutical Economics
Melphalan
Multiple Myeloma
Prednisone
Costs and Cost Analysis
Survivors
Therapeutics
Maintenance
Phase III Clinical Trials
Disease-Free Survival
Cost-Benefit Analysis
lenalidomide
Randomized Controlled Trials

Keywords

  • Cost-effectiveness
  • Lenalidomide
  • Maintenance
  • Multiple myeloma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myeloma. / Kim, Miriam Y.; Sposto, Richard; Swaika, Abhisek; Asano, Hitomi; Alamgir, Ahsan; Chanan Khan, Asher A; Ailawadhi, Sikander.

In: Oncology (Switzerland), Vol. 87, No. 4, 07.11.2014, p. 224-231.

Research output: Contribution to journalArticle

Kim, Miriam Y. ; Sposto, Richard ; Swaika, Abhisek ; Asano, Hitomi ; Alamgir, Ahsan ; Chanan Khan, Asher A ; Ailawadhi, Sikander. / Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myeloma. In: Oncology (Switzerland). 2014 ; Vol. 87, No. 4. pp. 224-231.
@article{fa203c1c84e94d83b736aded13e64618,
title = "Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myeloma",
abstract = "We compared the three arms of the MM-015 randomized phase III clinical trial [melphalan and prednisone (MP), MP plus lenalidomide (MPR), and MPR plus lenalidomide maintenance (MPR-R)] to determine whether the addition of lenalidomide maintenance therapy for primary treatment of multiple myeloma is cost-effective. We used progression-free survival and adverse event data from the MM-015 study for the analysis. Two novel measures of cost-effectiveness termed the Average Cumulative Cost per Patient (ACCP) and the Average Cumulative Cost per Progression-Free Survivor (ACCPFS) were developed for the purpose of this analysis. The ACCP of MP was USD 18,218, compared to USD 167,862 for MPR and USD 309,173 for MPR-R. The ACCPFS was highest with MPR at USD 1,555,443, while MP was USD 313,592 and MPR-R was USD 690,111. MPR-R is superior to MPR in terms of preventing the first progression after initial therapy. However, the addition of lenalidomide to MP in the induction and also in the maintenance setting leads to significant costs.",
keywords = "Cost-effectiveness, Lenalidomide, Maintenance, Multiple myeloma",
author = "Kim, {Miriam Y.} and Richard Sposto and Abhisek Swaika and Hitomi Asano and Ahsan Alamgir and {Chanan Khan}, {Asher A} and Sikander Ailawadhi",
year = "2014",
month = "11",
day = "7",
doi = "10.1159/000364880",
language = "English (US)",
volume = "87",
pages = "224--231",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "4",

}

TY - JOUR

T1 - Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myeloma

AU - Kim, Miriam Y.

AU - Sposto, Richard

AU - Swaika, Abhisek

AU - Asano, Hitomi

AU - Alamgir, Ahsan

AU - Chanan Khan, Asher A

AU - Ailawadhi, Sikander

PY - 2014/11/7

Y1 - 2014/11/7

N2 - We compared the three arms of the MM-015 randomized phase III clinical trial [melphalan and prednisone (MP), MP plus lenalidomide (MPR), and MPR plus lenalidomide maintenance (MPR-R)] to determine whether the addition of lenalidomide maintenance therapy for primary treatment of multiple myeloma is cost-effective. We used progression-free survival and adverse event data from the MM-015 study for the analysis. Two novel measures of cost-effectiveness termed the Average Cumulative Cost per Patient (ACCP) and the Average Cumulative Cost per Progression-Free Survivor (ACCPFS) were developed for the purpose of this analysis. The ACCP of MP was USD 18,218, compared to USD 167,862 for MPR and USD 309,173 for MPR-R. The ACCPFS was highest with MPR at USD 1,555,443, while MP was USD 313,592 and MPR-R was USD 690,111. MPR-R is superior to MPR in terms of preventing the first progression after initial therapy. However, the addition of lenalidomide to MP in the induction and also in the maintenance setting leads to significant costs.

AB - We compared the three arms of the MM-015 randomized phase III clinical trial [melphalan and prednisone (MP), MP plus lenalidomide (MPR), and MPR plus lenalidomide maintenance (MPR-R)] to determine whether the addition of lenalidomide maintenance therapy for primary treatment of multiple myeloma is cost-effective. We used progression-free survival and adverse event data from the MM-015 study for the analysis. Two novel measures of cost-effectiveness termed the Average Cumulative Cost per Patient (ACCP) and the Average Cumulative Cost per Progression-Free Survivor (ACCPFS) were developed for the purpose of this analysis. The ACCP of MP was USD 18,218, compared to USD 167,862 for MPR and USD 309,173 for MPR-R. The ACCPFS was highest with MPR at USD 1,555,443, while MP was USD 313,592 and MPR-R was USD 690,111. MPR-R is superior to MPR in terms of preventing the first progression after initial therapy. However, the addition of lenalidomide to MP in the induction and also in the maintenance setting leads to significant costs.

KW - Cost-effectiveness

KW - Lenalidomide

KW - Maintenance

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=84904535317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904535317&partnerID=8YFLogxK

U2 - 10.1159/000364880

DO - 10.1159/000364880

M3 - Article

C2 - 25059308

AN - SCOPUS:84904535317

VL - 87

SP - 224

EP - 231

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 4

ER -